{"title":"CAR-T细胞治疗t细胞恶性肿瘤:局限性和解决方案","authors":"Lingling Shan, Xiaoming Feng, Jing Pan","doi":"10.15212/hod-2022-0002","DOIUrl":null,"url":null,"abstract":"CD19-targeted chimeric antigen receptor (CAR)-T cell therapy has shown high potential for treating B-cell hematological malignancies and has been approved by the US FDA. However, CAR-T cell therapy for T-cell hematologic malignancies poses feasibility challenges, including the difficulty of obtaining sufficient healthy cells from patients, CAR-T cell fratricide, and the risk of immunodeficiency. In this review, we discuss bottlenecks and possible solutions in CAR-T cell therapy for T-cell acute lymphoblastic leukemias, as well as future directions in this field.","PeriodicalId":107466,"journal":{"name":"Hematology and Oncology Discovery","volume":"113 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CAR-T Cell therapy in T-cell malignancies: limitations and solutions\",\"authors\":\"Lingling Shan, Xiaoming Feng, Jing Pan\",\"doi\":\"10.15212/hod-2022-0002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"CD19-targeted chimeric antigen receptor (CAR)-T cell therapy has shown high potential for treating B-cell hematological malignancies and has been approved by the US FDA. However, CAR-T cell therapy for T-cell hematologic malignancies poses feasibility challenges, including the difficulty of obtaining sufficient healthy cells from patients, CAR-T cell fratricide, and the risk of immunodeficiency. In this review, we discuss bottlenecks and possible solutions in CAR-T cell therapy for T-cell acute lymphoblastic leukemias, as well as future directions in this field.\",\"PeriodicalId\":107466,\"journal\":{\"name\":\"Hematology and Oncology Discovery\",\"volume\":\"113 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology and Oncology Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15212/hod-2022-0002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology and Oncology Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15212/hod-2022-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CAR-T Cell therapy in T-cell malignancies: limitations and solutions
CD19-targeted chimeric antigen receptor (CAR)-T cell therapy has shown high potential for treating B-cell hematological malignancies and has been approved by the US FDA. However, CAR-T cell therapy for T-cell hematologic malignancies poses feasibility challenges, including the difficulty of obtaining sufficient healthy cells from patients, CAR-T cell fratricide, and the risk of immunodeficiency. In this review, we discuss bottlenecks and possible solutions in CAR-T cell therapy for T-cell acute lymphoblastic leukemias, as well as future directions in this field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
